

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number
WO 2005/00887 A1

(51) International Patent Classification⁷: **C07K 14/47**,
C12N 15/12, A61K 47/42, 38/17, A61P 35/00

(21) International Application Number:
PCT/IB2004/002165

(22) International Filing Date: 30 June 2004 (30.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/483,691 30 June 2003 (30.06.2003) US

(71) Applicant (for all designated States except US): UNIVER-
SITE DE LAUSANNE [CH/CH]; Bugnon 21, CH-1005
Lausanne (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WIDMANN, Chris-
tian [CH/CH]; Grangette 5D, CH-1010 Lausanne (CH).

YANG, Jiang-Yang [CN/CH]; Avenue Victor-Ruffy
30bis, CH-1012 Lausanne (CH). MICHOD, David
[CH/CH]; Chemin de Montmeillan 12, CH-1005 Lausanne
(CH).



(74) Agent: KATZAROV S.A.; Rue des Epinettes 19,
CH-1227 Geneve (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: RASGAP DERIVED PEPTIDE FOR SELECTIVELY KILLING CANCER CELLS



(57) Abstract: The present invention relates to a peptide consist-
ing in the N2 sequence of the RasGAP protein, a fragment thereof,
or a variant thereof which enhances the ability of a drug to selec-
tively kill cells. Furthermore, it relates to a pharmaceutical com-
position comprising as an active substance a pharmaceutically ef-
fective amount of said peptide.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

Declaration under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.